Onconova Therapeutics, Inc. Warrants
ONTXW
ONTXW was delisted on the 23rd of July, 2021.
5 hedge funds and large institutions have $634K invested in Onconova Therapeutics, Inc. Warrants in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
37% less capital invested
Capital invested by funds: $1M → $634K (-$366K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$350 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$39.8K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.25K |
ONTXW Hedge Fund Activity: Q4 2017 in Review
5 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Onconova Therapeutics, Inc. Warrants (ONTXW) for Q4 2017, worth a combined $634K — down 37% from $1M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ONTXW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $350. The largest seller was Boxer Capital, cutting an estimated $39.8K.
- 5 institutional investors held Onconova Therapeutics, Inc. Warrants (ONTXW) as of Q4 2017, up from 4 in Q3 2017.
- Funds reported $634K of Onconova Therapeutics, Inc. Warrants stock for Q4 2017, down 37% quarter-over-quarter.
- 1 fund opened new Onconova Therapeutics, Inc. Warrants positions in Q4 2017 and 0 closed out, a net change of +1 holder.
- The largest Onconova Therapeutics, Inc. Warrants buyer in Q4 2017 was UBS Group, an estimated $350 added.
- The largest Onconova Therapeutics, Inc. Warrants seller in Q4 2017 was Boxer Capital, an estimated $39.8K sold.
Based on aggregated 13F filings for Q4 2017.